Telix Pharmaceuticals Health Care
Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom

$11.22 -0.22 (-1.92%)

High $11.49	Low $11.20	Trades 4,718	Turnover $7,499,551	Volume 664,557
30 June 2023 at 4:12pm

Market Cap (2-Oct) $5,151,129,600 (204th)	Close (30-Jun) $11.22 0 (0%)	Volume (30-Jun) 664,557	Shortsold (29-Sep) 36,267,030 (10.67%) (12th)
52w High $18.22	52w Low $8.26	P/E 140.85	EPS 0.14

Short Interest

ASIC data, 29 Sep 2026

% Shorted

10.67% 0.08

vs 10.75% prior report

Most Shorted Rank

12th

of 693 shorted ASX stocks

Peak Short

16.51%

Apr 2026

Days to Cover

17.6

at 50d avg vol

View full short position history →

	Subject
	TLX TLX Ann: ZIRCON Phase 3 Imaging Study Completes Targets Enrolment
	1 (current) 2 3
	TLX TLX Ann: Cancellation of Share Purchase Plan
	TLX TLX Ann: FY21 Corporate Governance Statement - replacement
	TLX TLX Ann: Appendix 4G - Key to Governance Disclosures - replacement
	TLX TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act
	TLX TLX Ann: Application for quotation of securities - TLX
	TLX TLX Ann: 2021 Full Year Results Presentation
	TLX TLX Ann: Annual Report for the year ended 31 December 2021
	TLX TLX Ann: Corporate Governance Statement
	TLX TLX Ann: Appendix 4G - Key to Governance Disclosures
	TLX TLX Ann: Appendix 4E - Results for announcement to the market
	TLX TLX Ann: Commercial Distribution Agreement for Illuccix for Australia
	TLX TLX Ann: Ceasing to be a substantial holder
	TLX TLX Ann: Update - Proposed issue of securities - TLX
	TLX TLX Ann: Share Purchase Plan extended to Friday 25 February 2022
	TLX TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act 2001
	TLX TLX Ann: Application for quotation of securities - TLX
	TLX TLX Ann: Telix Granted Illuccix EU Regulatory Review Extension
	TLX TLX Ann: ZSP:Sydney Airport to be removed from the S&P/ASX 200 Index
	TLX TLX Ann: Application for quotation of securities - TLX
	TLX TLX Ann: Notice of change of interests of substantial holder
	TLX TLX Ann: Appendix 3Y - C Behrenbruch - exercise of options
	TLX TLX Ann: Telix Full Year Results and Investor Conference Call details
	TLX TLX Ann: Despatch of SPP Booklet to Eligible Shareholders
	TLX TLX Ann: App 3Y Change of Directors Interest Notice - A Kluge
	TLX TLX Ann: Notice of change of interests of substantial holder
	TLX TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act 2001
	TLX TLX Ann: Notice of change of interests of substantial holder
	TLX TLX Ann: Application for quotation of securities - TLX
	TLX TLX Ann: App 3Y Change of Directors Interest Notice - C Behrenbruch
	TLX TLX Ann: Cleansing Notice under S708A(5)(e) Corporations Act 2001
	TLX TLX Ann: Application for quotation of securities - TLX
	TLX TLX Ann: 1st Patient Dosed ProstACT Prostate Cancer Therapy Program
	TLX TLX Article: M&A boom reshaping the ASX one deal at a time
	TLX TLX Ann: Proposed issue of securities - TLX
	TLX TLX Ann: Appendix 4C and Activities Report for December 2021 Quarter
	TLX TLX Ann: Capital Raise Presentation
	TLX TLX Ann: Telix completes $175M placement and launches $25M SPP
	TLX TLX Article: Telix Pharma bulking up with $200m raising
	TLX TLX Ann: Trading Halt
	TLX TLX Ann: Investor Presentation to JP Morgan Healthcare Conference
	TLX TLX Ann: Notification of cessation of securities - TLX
	TLX TLX Ann: Targeted Alpha Therapy for Bladder Cancer 1st patient dosed
	TLX TLX Ann: FDA Approves Telix Prostate Cancer Imaging Product Illuccix
	TLX TLX Ann: Illuccix EU Regulatory Submission Progress Update
	TLX TLX Ann: NUCLIBER - Distribution Agreement for Illuccix in Spain
	TLX TLX Ann: Illuccix Granted Use Authorisation in Brazil
	TLX TLX Ann: Investor Presentation - November 2021
	TLX TLX Ann: Australian TGA Approves Illuccix for Prostate Cancer Imaging
	TLX TLX Ann: Activities Report and App 4C - September 2021 quarter

Similar Companies

CSL

Clinuvel Pharmaceuticals

CUV

Immutep

IMM

Imugene

IMU

Mesoblast

MSB

Opthea

OPT

Paradigm Biopharmaceuticals

PAR

PYC Therapeutics

PYC

Race Oncology

RAC

End of Day Prices

Date	Close	Volume	Change
02-Oct	$15.16	2,502,131	-0.45 (2.88%)
01-Oct	$15.61	1,618,652	-0.11 (0.70%)
30-Sep	$15.72	2,531,788	-0.43 (2.66%)
29-Sep	$16.15	1,975,751	+0.06 (0.37%)
28-Sep	$16.09	1,756,291	+0.19 (1.19%)
25-Sep	$15.90	1,553,094	+0.16 (1.02%)
24-Sep	$15.74	1,808,889	-0.34 (2.11%)
23-Sep	$16.08	3,343,138	-0.71 (4.23%)
22-Sep	$16.79	3,559,923	+1.03 (6.54%)
21-Sep	$15.76	4,324,837	-2.09 (11.71%)
18-Sep	$17.85	3,061,608	+0.40 (2.29%)
17-Sep	$17.45	2,265,947	+0.58 (3.44%)
16-Sep	$16.87	3,611,666	-0.88 (4.96%)
15-Sep	$17.75	6,075,869	+1.41 (8.63%)
14-Sep	$16.34	4,719,870	+0.67 (4.28%)
8 up, 7 down, and 0 flat days

Telix Pharmaceuticals Health Care
Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Telix Pharmaceuticals Health Care Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom

Short Interest

Followers

Prices

Announcements

Similar Companies

End of Day Prices

Telix Pharmaceuticals Health Care
Biotech Canada Cancer Healthcare Medical North America Pharmaceuticals United Kingdom